🏛️ Verified NIH Record • Updated 2026-07-10
Evaluation of the Pathobiology of CALR-mutated MPN Cells (NCT06480591)
🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Wake Forest University Health Sciences
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.
Who can join: Review the eligibility criteria below.
Location: Atrium Health Levine Cancer — Charlotte, North Carolina
Age range: 18 Years
🧪 Interventions in This Study
- Blood Draw (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Atrium Health Levine Cancer — Charlotte, North Carolina
- Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
📞 Contact the Study Coordinator
Phone: (980) 292-0817
Email: Courtney.Schepel@atriumhealth.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myeloproliferative Neoplasm
- A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm — Duarte, California
- Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms — Buffalo, New York
- An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms — Irvine, California
- Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms — Toronto, Ontario
Explore by condition: All Myeloproliferative Neoplasm clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.